

Universal group B streptococci screening not cost-effective

December 13 2016



(HealthDay)—For women with a singleton pregnancy planning a repeat

cesarean delivery, universal group B streptococci (GBS) screening is not cost-effective, according to a study published in the January issue of *Obstetrics & Gynecology*.

Catherine M. Albright, M.D., from the University of Washington in Seattle, and colleagues compared the cost-effectiveness of GBS screening for women planning a repeat cesarean delivery. With [universal screening](#), [prophylactic antibiotics](#) were given to all GBS-positive women who labored before a scheduled cesarean delivery. With no screening, antibiotic receipt was based on risk-based criteria for women who presented in labor.

The researchers found that universal GBS screening was not cost-effective in women planning a repeat cesarean delivery compared with no screening, with a cost of \$114,445 per neonatal quality-adjusted life-year gained. To prevent an adverse outcome from GBS, the cost exceeded \$400,000. Universal screening became cost-effective if more than 28 percent of women were GBS-positive, more than 29 percent labored before their scheduled delivery, or more than 10 percent delivered vaginally.

"Universal GBS screening in women with a singleton pregnancy planning a repeat cesarean delivery may not be cost-effective in all populations," the authors write. "However, in populations with a high GBS prevalence, women at high risk of laboring before their scheduled cesarean delivery, or [women](#) who may ultimately opt for a vaginal delivery, GBS screening may be cost-effective."

More information: [Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: Universal group B streptococci screening not cost-effective (2016, December 13)
retrieved 20 November 2023 from

<https://medicalxpress.com/news/2016-12-universal-group-streptococci-screening-cost-effective.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.